Last reviewed · How we verify
MTX-101
At a glance
| Generic name | MTX-101 |
|---|---|
| Sponsor | Mozart Therapeutics Australia Pty Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety, Pharmacokinetics, and Pharmacodynamics of MTX-101 in Healthy Adults and Patients (PHASE1)
- Safety and Efficacy Trial of MTX101 2mg for the Acute Treatment of Migraine in Adults (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MTX-101 CI brief — competitive landscape report
- MTX-101 updates RSS · CI watch RSS
- Mozart Therapeutics Australia Pty Ltd portfolio CI